顺铂和洛铂分别用于两药联合方案治疗晚期非小细胞肺癌的临床疗效观察

Clinical curative effect between gemcitabine combined with cisplatin and lobaplatin in the treatment of advanced nonsmall cell lung cancer

目的探讨顺铂和洛铂分别联合吉西他滨治疗晚期非小细胞肺癌的临床疗效及毒性反应。方法选取2013年8月~2015年8月于医院就诊的76例NSCLC患者为研究对象,将其分为A、B两组,各38例。A组化疗方案吉西他滨1000mg/m2,d1、d8静脉滴注;顺铂75mg/m2,d2静脉滴注;B组化疗方案吉西他滨1000mg/m2,d1、d8静脉滴注;洛铂30mg/m2,d2静脉滴注,两组均以21天为1个化疗周期。结果A组有效率(RR)为36.8%,疾病控制率(DCR)为78.9%;B组患者RR为28.9%,DCR为81.6%,两组RR与DCR比较差异均无统计学意义(P>0.05);骨髓抑制和肝肾功能损伤方面比较差异无统计学意义(P>0.05);B组患者胃肠道反应发生率显著低于A组,差异有统计学差异(P<0.05)。结论顺铂与洛铂联合吉西他滨治疗晚期非小细胞肺癌的临床疗效无差异,但洛铂联合吉西他滨对胃肠道的毒性较低,患者耐受较好。

Objective To discuss the clinical efficacy and toxicity of gemcitabine combined with cisplatin and lobaplatin in the treatment of advanced nonsmall cell lung cancer(NSCLC).Methods 76 patients with advanced NSCLC were divided into two groups,A group(n=38)was given gemcitabine 1000mg/m2 iv drip,d1 and d8,cisplatin 75mg/m2 iv drip,d2.B group(n=38)was given gemcitabine 1000mg/m2 iv drip,d1 and d8,lobaplatin 30mg/m2 iv drip,d2,21 days were a cycle.Results Effective rate and the disease control rate were 36.8% and 78.9% in group A,28.9% and 81.6% in group B,there was no statistical difference between the two groups(P>0.05),there was no statistically significant difference in marrow suppression rates and toxicity of liver and kidney(P>0.05),but the gastrointestinal reaction was significant lower in group B than in group A(P<0.05).Conclusion The clinical efficacy of gemcitabine combined with cisplatin is similar with lobaplatin in treating advanced nonsmall cell lung cancer,but the reaction of toxicity is lower in gemcitabine combined with lobaplatin compared with gemcitabine combined with cisplatin,which is more tolerable.